By Fineline Cube Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced the first patient enrollment in a Phase II clinical study evaluating opamtistomig (LBL-024) for first-line gastric or gastroesophageal junction adenocarcinoma, expanding the bispecific antibody’s development into a high-need oncology indication.
Drug Profile & Clinical Progress
| Attribute | Detail |
|---|---|
| Molecule | PD-L1/4-1BB bispecific antibody (BsAb) |
| Development Stage | Phase II across multiple indications |
| Key Indications | Non-small cell lung cancer, small cell lung cancer, extrapulmonary neuroendocrine carcinoma, gastric/gastroesophageal junction adenocarcinoma |
| Differentiation | Demonstrated first-in-class (FIC) or best-in-class (BIC) potential in registrational trials |
Regulatory Milestones Summary
| Designation | Authority | Indication | Date |
|---|---|---|---|
| Breakthrough Therapy Designation (BTD) | China NMPA | Advanced extrapulmonary neuroendocrine carcinoma (later-line) | Oct 2024 |
| Orphan Drug Designation | U.S. FDA | Neuroendocrine carcinoma | Nov 2024 |
| Fast Track Designation | U.S. FDA | Extrapulmonary neuroendocrine carcinoma | Jan 2026 |
| Orphan Drug Designation | European Commission | Extrapulmonary neuroendocrine carcinoma | Jan 2026 |
Strategic Significance
The expansion into gastric cancer represents a significant opportunity for Leads Biolabs, as gastric and gastroesophageal junction adenocarcinomas affect approximately 1.1 million patients globally each year with limited effective treatment options in the first-line setting. Opamtistomig’s dual mechanism—simultaneously targeting PD-L1 to block immune checkpoint inhibition and 4-1BB to stimulate T-cell activation—offers a novel approach to overcoming resistance mechanisms common in gastrointestinal malignancies.
The company’s robust regulatory recognition across major markets (China, U.S., EU) underscores the therapeutic potential of LBL-024 and positions it as a cornerstone asset in Leads Biolabs’ emerging oncology portfolio.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development and regulatory timelines. Actual outcomes may differ based on trial results, regulatory decisions, and competitive developments.-Fineline Info & Tech